drugset / Trial / NCT00250653

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

NCT00250653

Phase 3 Completed 365 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of saredutant in adult and elderly patients with depression. The secondary objective is to evaluate blood levels of saredutant.

Timeline

Start
2005-05
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Saredutant Small molecule 100 mg

Indications